{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:10:11Z","timestamp":1795108211647,"version":"4.10.3"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2021JDRC0045, 2021JDRC0169, 2021YJ0472, 2021YFS0164"],"award-info":[{"award-number":["2021JDRC0045, 2021JDRC0169, 2021YJ0472, 2021YFS0164"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["2019HXFH038, 2021HXFH018"],"award-info":[{"award-number":["2019HXFH038, 2021HXFH018"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The effectiveness of rituximab in anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis (DM) with interstitial lung disease (ILD) has been explored only in isolated case reports and small series. This paper aims to review the current evidence regarding rituximab (RTX) use in the treatment of ILD related to anti-MDA5 DM (anti-MDA5 DM-ILD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a review by searching PubMed, Web of Science, Embase, and Cochrane for articles with information on patients with anti-MDA5 DM and RTX treatment, published until August 2021, in English language. The selected studies listed variation in chest high-resolution computed tomography (HRCT) and\/or pulmonary function test (PFT) as a primary outcome, in patients with anti-MDA5 DM-related ILD after using RTX.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 145 potentially eligible articles, 17 were selected. The information gathered from a total of 35 patients with anti-MDA5 DM-ILD was reviewed, including 13 men and 22 women. Patient age at onset was 47.60 \u00b1 13.72 years old. A total of 11.43% (4\/35) of the patients were found to have chronic ILD (C-ILD) and 88.57% (31\/30) exhibited rapidly progressive ILD (RP-ILD). Most patients (29\/30) had typical DM rashes. Prior to RTX administration, the majority of patients (27\/35) were treated with medium- or high-dose glucocorticoids and at least one additional immunotherapeutic agent. With regard to RTX efficacy for ILD in anti-MDA5 DM, 71.43% (25\/35) of the patients responded to treatment. Skin rash also improved in more than half of the patients after RTX treatment. The most common side effects were infections, reported by 37.14% (13\/35) of the patients after using RTX.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>As a CD20 targeting drug, RTX is a promising therapeutic tool for anti-MDA5 DM-ILD, although the risk of infections should be considered before treatment. Further prospective controlled studies are required to evaluate the optimal RTX treatment regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42021289714<\/jats:uri>, identifier CRD42021289714.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.820163","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T04:43:40Z","timestamp":1642481020000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review"],"prefix":"10.3389","volume":"12","author":[{"given":"Chenjia","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qibing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in Myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.12.010","article-title":"Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) Dermatomyositis: A Concise Review With an Emphasis on Distinctive Clinical Features","volume":"78","author":"Kurtzman","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21992","article-title":"Anti-Melanoma Differentiation-Associated Protein 5-Associated Dermatomyositis: Expanding the Clinical Spectrum","volume":"65","author":"Hall","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22728","article-title":"Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis","volume":"68","author":"Moghadam-Kia","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B5","article-title":"Prevalence and Clinical Significance of Anti-MDA5 Antibodies in European Patients With Polymyositis\/Dermatomyositis","volume":"32","author":"Ceribelli","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21728","article-title":"Clinical Manifestations of Dermatomyositis and Clinically Amyopathic Dermatomyositis Patients With Positive Expression of Anti-Melanoma Differentiation-Associated Gene 5 Antibody","volume":"64","author":"Cao","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep375","article-title":"The RIG-I-Like Receptor IFIH1\/MDA5 is a Dermatomyositis-Specific Autoantigen Identified by the Anti-CADM-140 Antibody","volume":"49","author":"Nakashima","year":"2010","journal-title":"Rheumatol (Oxford)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.52","article-title":"Clinical Correlations With Dermatomyositis-Specific Autoantibodies in Adult Japanese Patients With Dermatomyositis: A Multicenter Cross-Sectional Study","volume":"147","author":"Hamaguchi","year":"2011","journal-title":"Arch Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2019.3634","article-title":"Clinical Features and Poor Prognostic Factors of Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis With Rapid Progressive Interstitial Lung Disease","volume":"29","author":"Motegi","year":"2019","journal-title":"Eur J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/2024869","article-title":"Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort With Dermatomyositis","volume":"2020","author":"Li","year":"2020","journal-title":"J Immunol Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/03009740802687455","article-title":"Association of Distinct Clinical Subsets With Myositis-Specific Autoantibodies Towards Anti-155\/140-kDa Polypeptides, Anti-140-kDa Polypeptides, and Anti-Aminoacyl tRNA Synthetases in Japanese Patients With Dermatomyositis: A Single-Centre, Cross-Sectional Study","volume":"38","author":"Fujikawa","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/art.41105","article-title":"Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.amjms.2017.07.013","article-title":"Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies","volume":"355","author":"Chen","year":"2018","journal-title":"Am J Med Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.resinv.2016.08.007","article-title":"Association of Anti-Aminoacyl-Transfer RNA Synthetase Antibody and Anti-Melanoma Differentiation-Associated Gene 5 Antibody With the Therapeutic Response of Polymyositis\/Dermatomyositis-Associated Interstitial Lung Disease","volume":"55","author":"Yoshida","year":"2017","journal-title":"Respir Investig"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(21)00181-9","article-title":"Safety and Efficacy of Rituximab in Patients With Diffuse Large B-Cell Lymphoma in Malawi: A Prospective, Single-Arm, Non-Randomised Phase 1\/2 Clinical Trial","volume":"9","author":"Kimani","year":"2021","journal-title":"Lancet Glob Health"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab Versus Cyclophosphamide in ANCA-Associated Renal Vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-Cell-Targeted Therapy With Rituximab in Patients With Rheumatoid Arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102406","article-title":"Treatment for Refractory Lupus Nephritis: Rituximab vs Triple Target Therapy","volume":"18","author":"Cervera","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PloS Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and Dermatomyositis (First of Two Parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120621","article-title":"Would a New Name Hasten the Acceptance of Amyopathic Dermatomyositis (Dermatomyositis Sine Myositis) as a Distinctive Subset Within the Idiopathic Inflammatory Dermatomyopathies Spectrum of Clinical Illness","volume":"46","author":"Sontheimer","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05530-5","article-title":"Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) Antibody-Positive Dermatomyositis Responds to Rituximab Therapy","volume":"40","author":"Ge","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical Evaluation of the Newcastle-Ottawa Scale for the Assessment of the Quality of Nonrandomized Studies in Meta-Analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.2.ats3-00","article-title":"Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment. International Consensus Statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4122-2","article-title":"Rituximab for Refractory Rapidly Progressive Interstitial Lung Disease Related to Anti-MDA5 Antibody-Positive Amyopathic Dermatomyositis","volume":"37","author":"So","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2015.1014140","article-title":"A Case of Anti-MDA5-Positive Rapidly Progressive Interstitial Lung Disease in a Patient With Clinically Amyopathic Dermatomyositis Ameliorated by Rituximab, in Addition to Standard Immunosuppressive Treatment","volume":"27","author":"Koichi","year":"2017","journal-title":"Modern Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5386797","article-title":"Effective Administration of Rituximab in Anti-MDA5 Antibody-Positive Dermatomyositis With Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review","volume":"2017","author":"Ogawa","year":"2017","journal-title":"Case Rep Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.56.7956","article-title":"Dermatomyositis With Rapidly Progressive Interstitial Lung Disease Treated With Rituximab: A Report of 3 Cases in Japan","volume":"56","author":"Tokunaga","year":"2017","journal-title":"Internal Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.13136","article-title":"Successful Multi-Target Therapy Including Rituximab and Mycophenolate Mofetil in Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Rapidly Progressive Interstitial Lung Disease With Clinically Amyopathic Dermatomyositis","volume":"20","author":"Hisanaga","year":"2017","journal-title":"Int J Rheumatic Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12890-018-0622-8","article-title":"MDA-5 Associated Rapidly Progressive Interstitial Lung Disease With Recurrent Pneumothoraces: A Case Report","volume":"18","author":"Alqatari","year":"2018","journal-title":"BMC Pulm Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2017.1334814","article-title":"Describing and Expanding the Clinical Phenotype of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease: Case Series of Nine Canadian Patients and Literature Review","volume":"47","author":"Hoa","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.53.2769","article-title":"Early Pulmonary Involvement of Anti-CADM-140 Autoantibody-Positive Rapidly Progressive Interstitial Lung Disease Preceding Typical Cutaneous Symptoms","volume":"53","author":"Tamai","year":"2014","journal-title":"Intern Med"},{"key":"B34","first-page":"A6475","article-title":"A Case of Rapidly Progressive Interstitial Pneumonia in Association With Amyopathic Dermatomyositis With Elevated Titers of Anti-MDA-5 Antibody, Successfully Treated With Rituximab in Addition to Standard Immunosuppressive Therapy","volume":"197","author":"Nishizawa","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04590-9","article-title":"Macrophage Activation Syndrome in Adult Dermatomyositis: A Case-Based Review","volume":"40","author":"Kishida","year":"2020","journal-title":"Rheumatol Int"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8145790","article-title":"Rituximab in Antimelanoma Differentiation-Associated Protein-5 Dermatomyositis With Interstitial Lung Disease","volume":"2020","author":"Scirocco","year":"2020","journal-title":"Case Rep Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e0026","DOI":"10.1097\/md9.0000000000000026","article-title":"Successful Concomitant Therapy With Tofacitinib for Anti- Melanoma Differentiation Associated Gene 5 Antibody-Positive Rapidly Progressive Interstitial Lung Disease With Poor Prognostic Factors: A Case Report and Literature Review","volume":"2","author":"Machiyama","year":"2021","journal-title":"Med: Case Rep Study Protoc"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04851-1","article-title":"Association of Various Myositis-Specific Autoantibodies With Dermatomyositis and Polymyositis Triggered by Pregnancy","author":"Akiyama","year":"2021","journal-title":"Rheumatol Int"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-240046","article-title":"Anti-MDA5 Antibody-Positive Dermatomyositis With Rapidly Progressive Interstitial Lung Disease: Report of Two Cases","volume":"14","author":"Mehta","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12969-021-00595-1","article-title":"Adolescent-Onset Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis With Rapidly Progressive Interstitial Lung Disease and Spontaneous Pneumomediastinum: A Case Report and Literature Review","volume":"19","author":"Yeung","year":"2021","journal-title":"Pediatr Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"105983","DOI":"10.1016\/j.rmed.2020.105983","article-title":"Ultra-Low Dose Rituximab as Add-on Therapy in Anti-MDA5-Positive Patients With Polymyositis\/Dermatomyositis Associated ILD","volume":"172","author":"Mao","year":"2020","journal-title":"Respir Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0562-9","article-title":"Adult Clinically Amyopathic Dermatomyositis With Rapid Progressive Interstitial Lung Disease: A Retrospective Cohort Study","volume":"26","author":"Ye","year":"2007","journal-title":"Clin Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-2740","article-title":"Clinical Differences Between Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis and Classic Dermatomyositis","volume":"136","author":"Mukae","year":"2009","journal-title":"Chest"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205278","article-title":"Basiliximab may Improve the Survival Rate of Rapidly Progressive Interstitial Pneumonia in Patients With Clinically Amyopathic Dermatomyositis With Anti-MDA5 Antibody","volume":"73","author":"Zou","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15117","article-title":"Elevated Serum B-Cell Activating Factor Levels in Patients With Dermatomyositis: Association With Interstitial Lung Disease","volume":"46","author":"Matsushita","year":"2019","journal-title":"J Dermatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key341","article-title":"CD4+CXCR4+ T Cells as a Novel Prognostic Biomarker in Patients With Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease","volume":"58","author":"Wang","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.773352","article-title":"Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies","volume":"12","author":"Nombel","year":"2021","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2016.1179861","article-title":"Abnormally Increased Low-Density Granulocytes in Peripheral Blood Mononuclear Cells are Associated With Interstitial Lung Disease in Dermatomyositis","volume":"27","author":"Zhang","year":"2017","journal-title":"Mod Rheumatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3799-y","article-title":"Neutrophil Extracellular Traps may Contribute to Interstitial Lung Disease Associated With Anti-MDA5 Autoantibody Positive Dermatomyositis","volume":"37","author":"Peng","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes012","article-title":"Hyperferritinaemia and Macrophage Activation in a Patient With Interstitial Lung Disease With Clinically Amyopathic DM","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez185","article-title":"Successful Classification of Macrophage-Mannose Receptor CD206 in Severity of Anti-MDA5 Antibody Positive Dermatomyositis Associated ILD","volume":"58","author":"Horiike","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16917","article-title":"Aberrant Activation of the Type I Interferon System may Contribute to the Pathogenesis of Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis","volume":"180","author":"Zhang","year":"2019","journal-title":"Br J Dermatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.900843","article-title":"Serum Interferon-Alpha is a Useful Biomarker in Patients With Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) Antibody-Positive Dermatomyositis","volume":"25","author":"Horai","year":"2015","journal-title":"Mod Rheumatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2001618","DOI":"10.1183\/13993003.01618-2020","article-title":"Similarities Between COVID-19 and Anti-MDA5 Syndrome: What can We Learn for Better Care","volume":"56","author":"Giannini","year":"2020","journal-title":"Eur Respir J"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0288-3","article-title":"RIG-I-Like Receptors: Their Regulation and Roles in RNA Sensing","volume":"20","author":"Rehwinkel","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.022637199","article-title":"Mda-5: An Interferon-Inducible Putative RNA Helicase With Double-Stranded RNA-Dependent ATPase Activity and Melanoma Growth-Suppressive Properties","volume":"99","author":"Kang","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.08.004","article-title":"Enhanced Skin Expression of Melanoma Differentiation-Associated Gene 5 (MDA5) in Dermatomyositis and Related Autoimmune Diseases","volume":"64","author":"Zahn","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.353557","article-title":"Neutrophils Express Distinct RNA Receptors in a Non-Canonical Way","volume":"287","author":"Berger","year":"2012","journal-title":"J Biol Chem"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V281345","article-title":"Murine Monoclonal Anti-DNA Antibodies Penetrate Cells, Bind to Nuclei, and Induce Glomerular Proliferation and Proteinuria","volume":"2","author":"Vlahakos","year":"1992","journal-title":"vivo J Am Soc Nephrol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/12.4.415","article-title":"In Vivo Cell Penetration and Intracellular Transport of Anti-Sm and Anti-La Autoantibodies","volume":"12","author":"Deng","year":"2000","journal-title":"Int Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"16833","DOI":"10.1038\/s41598-017-17007-8","article-title":"Essential Involvement of the CX3CL1-CX3CR1 Axis in Bleomycin-Induced Pulmonary Fibrosis via Regulation of Fibrocyte and M2 Macrophage Migration","volume":"7","author":"Ishida","year":"2017","journal-title":"Sci Rep"},{"key":"B62","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1365-2249.2012.04638.x","article-title":"Type I Interferon Induces CX3CL1 (Fractalkine) and CCL5 (RANTES) Production in Human Pulmonary Vascular Endothelial Cells","volume":"170","author":"Nakano","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2016.03.004","article-title":"Human Neutrophils in Auto-Immunity","volume":"28","author":"Thieblemont","year":"2016","journal-title":"Semin Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjd.14882","article-title":"Antimelanoma Differentiation-Associated Protein 5 Antibody Level is a Novel Tool for Monitoring Disease Activity in Rapidly Progressive Interstitial Lung Disease With Dermatomyositis","volume":"176","author":"Matsushita","year":"2017","journal-title":"Br J Dermatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21985","article-title":"Utility of Anti-Melanoma Differentiation-Associated Gene 5 Antibody Measurement in Identifying Patients With Dermatomyositis and a High Risk for Developing Rapidly Progressive Interstitial Lung Disease: A Review of the Literature and a Meta-Analysis","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20062567","article-title":"BAFF and MyD88 Signals Promote a Lupuslike Disease Independent of T Cells","volume":"204","author":"Groom","year":"2007","journal-title":"J Exp Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-012-0254-6","article-title":"Biologic Differences Between Various Inhibitors of the BLyS\/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development","volume":"14","author":"Stohl","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140977","article-title":"Increased Serum B Cell Activating Factor and a Proliferation-Inducing Ligand Are Associated With Interstitial Lung Disease in Patients With Juvenile Dermatomyositis","volume":"42","author":"Kobayashi","year":"2015","journal-title":"J Rheumatol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4296","article-title":"Interleukin-21: A Double-Edged Sword With Therapeutic Potential","volume":"13","author":"Spolski","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2013.04.083","article-title":"[Dermatomyositis and Acute Interstitial Lung Disease Associated With MDA-5 Antibodies: An Atypical Case]","volume":"140","author":"Girard","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1159\/000346573","article-title":"Response of Mucocutaneous Lesions to Rituximab in a Case of Melanoma Differentiation Antigen 5-Related Dermatomyositis","volume":"225","author":"Clottu","year":"2012","journal-title":"Dermatology"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 Antibody, Ferritin and IL-18 are Useful for the Evaluation of Response to Treatment in Interstitial Lung Disease With Anti-MDA5 Antibody-Positive Dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1080\/08830185.2017.1346092","article-title":"Risk Factors Predisposing to the Development of Hypogammaglobulinemia and Infections Post-Rituximab","volume":"36","author":"Christou","year":"2017","journal-title":"Int Rev Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2019.1624706","article-title":"The Efficacy and Safety of Low-Dose Rituximab in Immune Thrombocytopenia: A Systematic Review and Meta-Analysis","volume":"30","author":"Li","year":"2019","journal-title":"Platelets"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a1aac7","article-title":"Responsiveness to Reduced Dosage of Rituximab in Chinese Patients With Neuromyelitis Optica","volume":"81","author":"Yang","year":"2013","journal-title":"Neurology"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2017.04.007","article-title":"Lower Dosages of Rituximab Used Successfully in the Treatment of Anti-NMDA Receptor Encephalitis Without Tumour","volume":"377","author":"Wang","year":"2017","journal-title":"J Neurol Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.820163\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T04:43:44Z","timestamp":1642481024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.820163\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":76,"alternative-id":["10.3389\/fimmu.2021.820163"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.820163","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2021.820163.s001","asserted-by":"subject"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"article-number":"820163"}}